Leerink Swann Reiterates an 'Outperform' on Ardea Biosciences (RDEA); Positive Phase IIb Data for RDEA594 Monotherapy De-Risks Gout Program
Tweet Send to a Friend
This morning, Leerink Swann reiterated an 'Outperform' rating on Ardea Biosciences (Nasdaq: RDEA) and raises its price target from $20 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
